Investing in Ardelyx, Inc. (ARDX)  ➔  Intrinsic value

Prev. close$7.12 
ModelValueUpside
Chepakovich$1.11-84%
Graham-Dodd$0.00-100%
Graham$33.25+367%
Previous Close$7.12  
Valuation MethodValuePotential 
Chepakovich Model$1.11-84%recalculate
Graham-Dodd$0.00-100%recalculate
Graham Formula$33.25+367%recalculate

Latest news

Company description

Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.